HESKA CORP

Delisted

CIK 1038133fmd_0KW4AJETD157WSHEMFRZXS689GManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jan 01, 2009 to Mar 31, 2023, 53 periods

Income Statement · Annual · Millions · USD
Line item	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022
Total revenues	78	90	105	130	129	127	123	197	254	257
Rental revenue	–	–	–	–	–	–	0	1	2	2
Cost of revenue	48	54	60	76	71	71	68	116	148	146
Gross profit	31	36	44	54	58	57	54	81	106	111
Provision for credit losses	–	–	–	–	–	0	0	1	0	0
Research and development	2	1	2	2	2	3	8	9	7	20
Selling, general and administrative	31	31	34	35	38	50	46	81	100	112
Total operating expenses	32	33	36	37	40	53	54	89	107	131
Operating income	(1)	3	9	17	18	4	0	(8)	(1)	(20)
Interest expense	0	0	0	0	0	0	3	6	4	4
Interest and investment income	0	0	(0)	(0)	–	–	–	–	–	–
Other non-operating income (expense)	–	–	(0)	(0)	0	0	(3)	(6)	(2)	(2)
Income before taxes	(1)	3	8	17	18	4	(3)	(14)	(3)	(22)
Income tax expense	(0)	1	3	4	9	(2)	(1)	0	(4)	(3)
Net income from continuing operations	(1)	2	6	12	9	6	(1)	(14)	0	(18)
Net income	(1)	3	5	11	10	6	(1)	(14)	(1)	(20)